<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2021-25-6-93-98</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2056</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Этиология и клинико-морфологическая презентация С3-гломерулопатии (одноцентровое исследование 60 случаев)</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and morphological presentation of C3 glomerulopathy: a single-center study of 60 cases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7179-5520</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Добронравов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dobronravov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Профессор Добронравов Владимир Александрович - доктор медицинских наук, исполняющий обязанности директора научно-исследовательского института нефрологии, кафедра пропедевтики внутренних болезней с клиникой.</p><p>197022, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54. Тел.: +7(812)338-69-01</p></bio><bio xml:lang="en"><p>Prof. Vladimir A. Dobronravov - MD, PhD, DMedSci, acting Director, Department of Propedeutics of Internal Diseases, professor.</p><p>197022, St. Petersburg, L. Tolstoy st., 17, build 54. Phone: +7(812)338-69-01</p></bio><email xlink:type="simple">dobronravov@nephrolog.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0758-8137</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карунная</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Karunnaya</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карунная Анна Викторовна - врач-нефролог, научно-исследовательский институт нефрологии, заведующая отделением хронического гемодиализа, ассистент кафедры пропедевтики внутренних болезней с клиникой.</p><p>197022, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54. Тел.: +7(812)338-69-14</p></bio><bio xml:lang="en"><p>Anna V. Karunnaya - MD, Head of the Department of Chronic Hemodialysis, assistant of the Department of Propaedeutics of Internal Diseases.</p><p>197022, St. Petersburg, L. Tolstoy st., 17, build 54. Phone: +7(812)338-69-14</p></bio><email xlink:type="simple">a.v.karunnaya@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт нефрологии, Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Nephrology, Pavlov University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>18</day><month>11</month><year>2021</year></pub-date><volume>25</volume><issue>6</issue><fpage>93</fpage><lpage>98</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Добронравов В.А., Карунная А.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Добронравов В.А., Карунная А.В.</copyright-holder><copyright-holder xml:lang="en">Dobronravov V.A., Karunnaya A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2056">https://journal.nephrolog.ru/jour/article/view/2056</self-uri><abstract><sec><title>ВВЕДЕНИЕ</title><p>ВВЕДЕНИЕ. СЗ-гломерулопатия (С3-ГП) представляет собой спектр заболеваний, развитие которых обусловлено дис-регуляцией альтернативного пути комплемента. Настоящее исследование проведено с учетом ограниченного числа зарубежных и отсутствия отечественных оригинальных исследований, касающихся этой орфанной патологии почек.</p></sec><sec><title>ЦЕЛЬ ИССЛЕДОВАНИЯ</title><p>ЦЕЛЬ ИССЛЕДОВАНИЯ. Анализ клинико-морфологических проявлений СЗ-ГП на момент первичной диагностики.</p></sec><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. Ретроспективное исследование с анализом этиологии, клинических данных и морфологических изменений почек среди случаев СЗ-ГП, выявленных в период 2006-2021 гг.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. В исследование включено 60 случаев. Средний возраст пациентов - 43±17 лет. Нефротический синдром выявлен у 47 % больных; в 58 % случаев расчетная скорость клубочковой фильтрации была &lt;60 мл/мин/1,73 м2. Доминирующим морфологическим паттерном явился мембранопролиферативный гломерулонефрит (75 % случаев). В 2 случаях СЗ-ГП дебютировала клиникоморфологическими проявлениями болезни минимальных изменений, в которых выявление характерных элекронно-плотных депозитов стало очевидным при выполнении повторной биопсии. 4 случая имели в дебюте классические признаки комплемент-опосредованной тромботической микроангиопатии (атипичного гемолитико-уремического синдрома) в сочетании с СЗ-ГП или ее последующего развития. На основании ультраструктурного исследования (n=40), 80 % случаев были отнесены к СЗ-гломерулонериту, остальные - к болезни плотных депозитов. Первичная СЗ-ГП выявлена у 87 % пациентов, вторичная - у 1З % (моноклональные гаммапатии - 10 %, аутоиммунные заболевания - З %). Наличие повышенного уровня антител к фактору Н выявлено у 2 из 12 пациентов, которым было выполнено это исследование. В 2 из 6 случаев при выполнении молекулярно-генетического исследования с целью выявления мутаций генов комплемента выявлены нуклеотидные варианты неизвестного клинического значения.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. СЗ-ГП представляет собой тяжелый вариант повреждения клубочков с гетерогенной этиологической структурой, который требует применения ультраструктурной и молекулярной диагностики, а также клинического анализа и идентификации механизмов патогенеза для определения подходов к терапии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>INTRODUCTION</title><p>INTRODUCTION. СЗ-glomerulopathy (СЗ-GP) is a spectrum of diseases caused by dysregulation of the alternative complement pathway. The present study was carried out taking into account the limited number of foreign and the absence of original studies in the Russian population.</p></sec><sec><title>THE AIM</title><p>THE AIM. Analysis of clinical and morphological manifestations of СЗ-GP at the time of primary diagnosis.</p></sec><sec><title>PATIENTS AND METHODS</title><p>PATIENTS AND METHODS. Retrospective analysis of the etiology, clinical data and morphology of СЗ-GP identified in the period 2006-2021.</p></sec><sec><title>RESULTS</title><p>RESULTS. The study included 60 cases. The average age of patients is 4З±17 years. Nephrotic syndrome was detected in 47 % of patients; in 58 % of cases the estimated glomerular filtration rate was &lt;60 ml/ min/иЗ m2. The dominant morphological pattern was membranoproliferative glomerulonephritis (75% cases). In 2 cases, СЗ-GP debuted with clinical and morphological manifestations of the disease of minimal changes, in which the identification of characteristic electron-dense deposits became obvious when performing a second biopsy. 4 cases had at the onset classical signs of complement-mediated thrombotic microangiopathy (atypical hemolytic uremic syndrome) in combination with C3-GP or its subsequent development.Ultrastructural examination was performed in 40 cases. 8 patients (20%) were diagnosed dense deposit disease, 32 patients - C3-glomerulonephritis. Primary C3-GP was detected in 87 % of patients, secondary - in 13 % (monoclonal gammopathies - 10 %, autoimmune diseases - 3 %).Increased level of antibodies to factor H was detected in 2 of 12 patients who underwent this study. Nucleotide variants of unknown clinical significance in complement genes were detected in 2 out of 6 patients during molecular genetic testing.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. C3-GP is a severe variant of glomerular damage with a heterogeneous etiological structure, which requires the use of ultrastructural and molecular diagnostics, as well as clinical analysis and identification of pathogenetic mechanisms to determine approaches to therapy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>СЗ-гломерулопатия</kwd><kwd>СЗ-гломерулонефрит</kwd><kwd>болезнь плотных депозитов</kwd><kwd>клинические проявления</kwd><kwd>морфологическая диагностика</kwd><kwd>клинико-морфологические корреляции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>C3 glomerulopathy</kwd><kwd>C3 glomerulonephritis</kwd><kwd>dense deposit disease</kwd><kwd>clinical manifestations</kwd><kwd>morphological diagnostics</kwd><kwd>clinical and morphological correlations</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84(6):1079-1089. doi: 10.1038/ki.2013.377</mixed-citation><mixed-citation xml:lang="en">Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84(6):1079-1089. doi: 10.1038/ki.2013.377</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91(3):539-551. doi: 10.1016/j.kint.2016.10.005</mixed-citation><mixed-citation xml:lang="en">Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91(3):539-551. doi: 10.1016/j.kint.2016.10.005</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Schena FP, Esposito P, Rossini M. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. Int J Mol Sci 2020;21(2):525. doi: 10.3390/ijms2102052</mixed-citation><mixed-citation xml:lang="en">Schena FP, Esposito P, Rossini M. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. Int J Mol Sci 2020;21(2):525. doi: 10.3390/ijms2102052</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bomback AS, Santoriello D, Avasare RS et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018;93(4):977-985. doi: 10.1016/j.kint.2017.10.022</mixed-citation><mixed-citation xml:lang="en">Bomback AS, Santoriello D, Avasare RS et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018;93(4):977-985. doi: 10.1016/j.kint.2017.10.022</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ravindran A, Fervenza FC, Smith RJH et al. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin Proc 2018;93(8):991-1008. doi: 10.1016/j.mayocp.2018.05.019</mixed-citation><mixed-citation xml:lang="en">Ravindran A, Fervenza FC, Smith RJH et al. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin Proc 2018;93(8):991-1008. doi: 10.1016/j.mayocp.2018.05.019</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rabasco C, Cavero T, Roman E et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88(5):1153-1160. doi: 10.1038/ki.2015.227</mixed-citation><mixed-citation xml:lang="en">Rabasco C, Cavero T, Roman E et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88(5):1153-1160. doi: 10.1038/ki.2015.227</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9(1):46-53. doi: 10.2215/CJN.04700513</mixed-citation><mixed-citation xml:lang="en">Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9(1):46-53. doi: 10.2215/CJN.04700513</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Iatropoulos P Daina E, Curreri M et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol 2018;29(1):283-294. doi: 10.1681/ASN.2017030258</mixed-citation><mixed-citation xml:lang="en">Iatropoulos P Daina E, Curreri M et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol 2018;29(1):283-294. doi: 10.1681/ASN.2017030258</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nakagawa N, Mizuno M, Kato S et al. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One 2021;16(9):e0257397. doi: 10.1371/journal.pone.0257397</mixed-citation><mixed-citation xml:lang="en">Nakagawa N, Mizuno M, Kato S et al. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One 2021;16(9):e0257397. doi: 10.1371/journal.pone.0257397</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Добронравов ВА, Смирнов АВ. Мембранопролиферативный гломерулонефрит в российской популяции. Тер архив 2018;90(12):39-47. doi: 10.26442/00403660.2018.12.000007</mixed-citation><mixed-citation xml:lang="en">Dobronravov VA, Smirnov AV. Membranoproliferative glomerulonephritis in Russian population.Therapeutic archive2018;90(12):39–47 (In Russ.) doi: 10.26442/00403660.2018.12.000007</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ankawi GA, Clark WF. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases? BMJCase Rep 2017;2017:bcr2017220974. doi: 10.1136/bcr-2017-220974</mixed-citation><mixed-citation xml:lang="en">Ankawi GA, Clark WF. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases? BMJCase Rep 2017;2017:bcr2017220974. doi: 10.1136/bcr-2017-220974</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Busutti M, Diomedi-Camassei F, Donadelli R et al. Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome. Kidney Int Rep 2020;6(2):534-537. doi: 10.1016/j.ekir.2020.10.037</mixed-citation><mixed-citation xml:lang="en">Busutti M, Diomedi-Camassei F, Donadelli R et al. Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome. Kidney Int Rep 2020;6(2):534-537. doi: 10.1016/j.ekir.2020.10.037</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hou J, Markowitz GS, Bomback AS et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014;85(2):450-456. doi: 10.1038/ki.2013.340</mixed-citation><mixed-citation xml:lang="en">Hou J, Markowitz GS, Bomback AS et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014;85(2):450-456. doi: 10.1038/ki.2013.340</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
